CDC42 and prostate cancer: Both RAC1-specific and dual RAC1/CDC42 inhibitors (NSC23766 and AZA1, respectively) have shown preclinical efficacy in prostate cancer cell lines (including PTEN-null PC-3 cells), inhibiting both cell migration and in vivo tumor growth [288,289].